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TCT-798
Long-term Follow-up of Mitral Valvuloplasty with Single Balloon. Independent
Predictors of Survival and Event Free Survival
Edison S Peixoto2, 3, Ricardo S Peixoto1, 2, Rodrigo S Peixoto2, Ivana P Borges2,
Paulo S Oliveira2, Aristarco G Siqueira-Filho1
1Rio de Janeiro Federal University, Rio de Janeiro, Brazil; 2Cinecor Evangelico
Hospital, Rio de Janeiro, Brazil; 3Fluminense Federal University, Niteroi, Brazil
Background: Mitral balloon valvuloplasty (MBV) with single balloon MBVSB) is
the less expensive technique to perform MBV with similar outcome and long-term
follow-up (FU) when compared with Inoue balloon technique
Methods: From 1987 to 2010, 526 procedures of MBV was performed, 404 (77.1%)
with MBVSB Balt, being 256 with long-term FU. Mean dilatation area was 7.02±0.30
cm2 and the FU 54.6±32.8 months. To determine independent predictors of survival
and event free survival (EFS) it was used the multivariate Cox analysis.
Results: Mean age was 38.0±12.6 years, being 222 (86.7%) female, 215 (84.0%)
patients in sinus rhythm and echo score 7.2± 1.5 points. Mean pre and post-MVA
(Gorlin) were 0.90±0.20 and 2.02±0.37 cm2 (p<0.001) and we had success MVA ≥1,5
cm2 in 241 (94.1%) procedures. Three (1.2%) patients began the FU with severe mitral
regurgitation (MR). At the end of the FU 119 (46.5%) patients were in NYHA FC I,
70 (27.3%) in FC II, 53 (20.7%) in FC III, 3 (1.2%) in FC IV and there were 11 deaths
(4.3%). There were 17 (8.2%) patients with new severe MR at the end of the FU, twelve
(4.7%) were submitted to new MBV, 27 (10.5%) to mitral valve surgery and 70 (26.3%)
used no medication at the end of the FU. Independent predictors of survival were: echo
score ≤8 (p<0.001, HR=0.116, 95% IC 0.035-0.384), age ≤ 50 years old (p=0.011, HR
0.203, 95% IC 0.059-0.693) and absence of mitral surgery in the evolution (p=0.004,
HR 0.170, 95% IC 0.050-0.571) in multivariate analysis with 6 or 7 variables.
Independent predictors of EFS were: absence of prior comissurotomy (p<0.002, HR
0.318, 95% IC 0.151-0.667), female gender (p=0.036, HR 0.466, 95% IC 0.229-0.951)
and MVA post MBV ≥ 1.50 cm2 (p<0.001, HR 0.466, 95% IC 4.884-28.457) in
multivariate analysis.
Conclusion: MBVSB Balt was efficient with durable results similar to other
techniques. Independents predictors of survival were: echo score ≤8, age ≤ 50 years
old and absence of mitral surgery in the evolution. Independent predictors of EFS were:
absence of prior comissurotomy, female gender and MVA post MBV ≥1.50 cm2.
TCT-799
Functional vs. Degenerative Mitral Regurgitation in Patients not Amenable to
Surgery Undergoing MitraClip Treatment
Stephan Baldus1, Volker Rudolph1, Michael Schlueter1, Olaf Franzen2, 1, Malgorzata
Knap1, Hendrik Treede1, Hermann Reichenspurner1, Stefan Blankenberg1
1University Heart Center, Hamburg, Germany; 2Rigshospitalet, Copenhagen,
Denmark
Background: Transcatheter MitraClip (MC; Abbott Vascular, IL) implantation is a
viable therapeutic option in patients (pts) with both degenerative (DMR) and functional
mitral regurgitation (FMR). The impact of MR etiology on acute and mid-term
outcomes of MC therapy has not been sufficiently elucidated.
Methods: Of 104 consecutive MC pts (all in NYHA III/IV; 103 with MR 3+/4+; 74 ±
9 years; 64 men) adjudicated not amenable to surgery, 69 pts (66%) had FMR and 35
pts had DMR. The latter tended to be older (mean 76 vs. 73 years, p=0.09), had less
often cardiomyopathy, significantly lower LV dimensions, and significantly better LV
function (mean EF 56% vs. 37%, p<0.0001). Follow-up was assessed at 1 year
(median) post-MC.
Results: Device success (MR ≤2+) was achieved in 30 DMR (86%) and 66 FMR pts
(96%, p=0.12); in successfully treated pts, DMR tended to require more often multiple
clips (50% vs. 29%, p=0.06). Clinical follow-up (FU) at 1 year was obtained from 24
DMR (80%) and 57 FMR pts (86%), echocardiographic FU from 19 DMR (63%) and
44 FMR pts (64%). Improvement in NYHA class was observed in 22/24 DMR pts
(92%) and 43/57 FMR pts (75%, p=0.13). Six-minute walk distance improved in 14/16
DMR pts (88%) and 27/39 FMR pts (69%, p=0.19) by 172 and 105m, respectively
(p=0.34). Improvement in Minnesota QoL score (-18 points in both groups) was
reported by 10/10 DMR pts (100%) and 25/37 FMR pts (68%, p=0.046). MR grade at
FU was improved in 18/19 DMR pts (95%) and 39/44 FMR pts (89%, p=0.66), with
MR 1+/2+ in 17 (90%) DMR and 35 (80%, p=0.48) FMR pts. Significant median
reductions in LV end-diastolic volume were present in both groups (DMR: -33ml,
p=0.003; FMR: -28ml, p<0.0001), as were significant median increases in forward
stroke volume (DMR: 7ml, p=0.04; FMR: 6ml, p=0.0005). One-year estimates of
survival free from death, rehospitalization or reintervention were 54.1% in DMR and
48.8% in FMR pts (p=0.91).
Conclusion: Despite a tendency toward lower device success in DMR pts, MC therapy
in pts not amenable to surgery appears to be clinically efficacious at 1 year regardless
of MR etiology.
TCT-800
Quality Of Life Changes In High Risk Patients after Percutaneous Mitral Valve
Repair with Mitraclip
Maurizio Taramasso, Paolo Denti, Micaela Cioni, Nicola Buzzatti, Antonio
Colombo, Ottavio Alfieri, Francesco Maisano
Cardiac Surgery, San Raffaele Scientific Institute, Milan, Italy
Background: Percutaneous mitral valve repair with the Mitraclip System is a
therapeutic option for selected patients with severe symptomatic mitral regurgitation
(MR). The aim of the study was to investigate the changes of QoL following Mitraclip
implantation in a series of consecutive high risk patients.
Methods: From October 2008 to April 2011, 76 consecutive patients with severe MR
underwent Mitraclip implantation at our Institution (32% degenerative; 68% functional;
mean age 71,3±11,4 years). Mean Log-EuroScore was 20,6±13,3% (18,3±9,2% for
degenerative; 21,6±24,7% for functional). Mean LVEF was 60,2±6,9 for degenerative
and 27,7±10,0 for functional. All patients underwent a standardized prospective
screening pathway, including QoL evaluation with the Short-Form Health Survey 36-
Item (SF-36v2®) and the Minnesota Living with Heart Failure Questionnaires
(MLHFQ). The scores obtained preoperatively were compared with those obtained at
latest follow-up.
Results: Procedural success rate was 97,4% (2/76 conversion to surgery due to leaflet
rupture). In-hospital mortality was 1,3% (1 patient converted to surgery died from
mediastinitis). Follow up was 100% complete (median 178 days; IQR 78,3-346,5 days).
Actuarial 1,5 years survival was 89,8±6,1% (95,6±4,3% for degenerative; 89,1±7,2%
for functional -p=0,06). At last follow-up, 84,2% of the patients had MR≤2+. A
significant improvement of LVEF was observed in the functional MR group (from
28,3±10% to 35,5±10,1%, p<0,0001). Mean SF36-physical improved from 35,2±9,1
to 43,2±9,0 (p<0,003) and SF36-mental improved from 42,0±8,7 to 49,4±7,1
(p=0,003). MLHFQ decreased from 36,3±13,9 to 18,4±16,4 (p<0,0001). QoL changes
were not influenced by age, comorbidities and MR etiology.
Conclusion: Mitraclip repair in selected high risk patients is associated with excellent
short and long term mortality and with substantial improvement of QoL, regardless of
age, comorbidities and MR etiology.
TCT-801
The Impact of Commissural Morphology on Clinical Outcome in Patients
Undergoing Percutaneous Balloon Mitral Valvuloplasty
Mohamed Ahmed Sadaka, Eman Elsharkawy, Magdy Rashwan, Rasha Abdo
cardiovascular, Alexandria University, Alexandria, Egypt
Background: Commissural morphology has a prognostic value on the immediate and
short term outcome after Percutaneous balloon mitral valvuloplasty despite of the low
Wilkin’s echocardiographic score.
Methods: The study included 30 patients with symptomatic mitral stenosis scheduled
for percutaneous balloon mitral valvuloplasty using multitrack system for 30 patients,
they were randomized prospectively into 2 groups: Group (1): 12 patients with only 1
mitral commissure was opened after the procedure. Group (2): 18 patients with both
mitral commissures were opened after the procedure
Results: Immediate follow up: no patient developed atrial fibrillation, embolization
or severe degree of regurgitation . The mean mitral valve area increased from 0.94±0.19
cm2 to 1.86± 0.27 cm2 in group 1 & from 0.91±0.18 to 2.29±0.33 cm2 in group 2
(p=0.001). The mean transmitral gradient decreased from 21.83+4.1 to 8.08±2.9mmHg
in group (1) and from 18.28±5 mmHg to 5.2±1.76 mmHg in group 2 (p=0.003). Three
months follow up: During follow up no recorded cases of death, hospital admission,
redo, or surgery &most of them in NYHA functional class 1-2. The mitral valve area
ranged between (1.6-2.1) with mean 1.8 cm2 in group 1 and ranged between (1.8-3.1)
with mean 2.2 cm2 in group 2 (p=0.001). The mean Transmitral gradient ranged
between (3-12) with mean 8.08 mmHg in group 1 and ranged between (3-9) with mean
5.47 mmHg in group 2 (p=0.001).
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commissural morphology
Conclusion: We concluded that commissural opening degree and mitral valve area are
closely related. The degree of commissural opening provides important prognostic
information, and complete commissural opening is associated with better late
functional results. Thus, degree of commissural opening should be systematically
evaluated during and after balloon mitral comissurotomy and can be considered as a
complementary measure of the procedural success in addition to the mitral valve area.
TCT-802
MitraClip Treatment of Functional Mitral Regurgitation in Patients not
Amenable to Surgery
Volker Rudolph1, Michael Schlueter1, Olaf Franzen2, 1, Malgorzata Knap1, Hendrik
Treede1, Hermann Reichenspurner1, Stefan Blankenberg1, Stephan Baldus1
1University Heart Center, Hamburg, Germany; 2Rigshospitalet, Copenhagen,
Denmark
Background: Transcatheter implantation of the MitraClip (MC; Abbott, Abbott Park,
IL) has evolved as a viable option to treat moderate/severe mitral regurgitation (MR).
The recent EVEREST II trial suggested that elderly patients (pts) with functional MR
and impaired LV function may particularly benefit from this therapeutic approach.
Methods: We studied 69 consecutive pts with functional MR (73 ± 8 years; 46 men
[67%]) who were attested a prohibitive surgical risk (median EuroSCORE 33%) by
joint (“heart team”) consensus of cardiovascular surgeons and cardiologists. Baseline
MR grade was 3+ (n=37) or 4+ (n=32) and mean LVEF was 37 ± 13%; all pts were in
NYHA functional class III or IV. Exclusion criteria of EVEREST trials were met in 56
pts (81%). All pts underwent MC therapy as previously described.
Results: Device success (residual MR ≤2+) was achieved in 66 pts (96%), with ≥2
clips implanted in 21 pts (30%). At discharge, 39 pts had MR 2+ and 27 had MR 1+.
Clinical and echocardiographic follow-up (FU) at 373 days (median) was obtained
from 57 and 44 pts, respectively. Functional improvement was noted in 43/57 pts
(75%), with 37/57 pts (64%) in NYHA class I or II. Six-minute walk distance improved
in 27/39 pts (69%) by 105 m – a 50% increase – and the Minnesota quality-of-life
score improved by -18 points – a 43% decrease – in 25/37 pts (68%). At FU, MR grade
was improved over baseline in 89% of pts (39/44); 80% of pts (35/44) had MR 1+ or
2+. LV end-diastolic and end-systolic volumes decreased significantly (median 210
vs. 239 ml [p<0.0001] and 127 vs. 136 ml [p=0.0012], respectively), whereas forward
stroke volume increased (median 49 vs. 42 ml [p=0.0005]). Kaplan-Meier 1-year
estimates of survival free from rehospitalization for cardiac decompensation and
survival free from death, rehospitalization or reintervention were 64.5% and 48.8%,
respectively.
Conclusion: MC therapy is feasible and efficacious in elderly pts with functional MR
not amenable to surgery who mostly would have been excluded from EVEREST. Thus,
MC implantation evolves as a novel treatment strategy in heart failure patients with
concomitant MR.
TCT-803
Changes in Platelet, Coagulation, Fibrinolytic Activities in Mitral Stenosis After
Percutaneous Mitral Valvotomy. Role of Hemodymamic Changes and Systemic
Inflammation
Hosam Hasan-Ali, Eman Mosad
Assiut University Hospitals, Assiut, Egypt
Background: Few reports demonstrated that increased inflammatory markers as well
as platelet, coagulation, fibrinolytic activities in mitral stenosis (MS) decrease after
percutaneous mitral valvotomy (PMV). The relationship between the inflammatory
markers and platelet, coagulation, and fibrinolytic activities was not studied before.
Methods: The study included 65 patients with MS undergoing PMV, and 23 controls.
Markers of platelet activity (P-Selectin), thrombin activity (Prothrombin fragment1,2
“PF1,2” and thrombin antithrombin complex “TAT”), fibrinolysis (D-Dimer), and
inflammation (interleukin 1B “IL1B”) were measured from venous samples obtained
before and 2 weeks after PMV and in all controls.
Results: All hemostatic and inflammatory markers were significantly higher in MS
patients than the control and they significantly decreased after PMV. Only in PF1,2
the level became not significantly different from the control after PMV. The change in
any of these variables didn’t correlate with the change in mitral valve area, mean
transmitral pressure gradient, left ventriculat dimensions and function. P-selectin
change was predicted by the changes in left atrial diameter “LAd” (r 0.4, P 0.02),
pulmonary artery systolic pressure “PASP” (r 0.3, P 0.02) and IL1B (r 0.7, P <0.0001).
D-dimer change had similar predictors; LAd (r 0.5, P <0.0001), PASP (r 0.3, p 0.04),
and IL1B (r 0.5, P <0.0001). PF1,2 change was predicted with the change in IL1B (r
0.8, P <0.0001). TAT change was predicted by the changes in LAd (0.3, P 0.02) and
right ventricular diameter “RVd” (r 0.3, P 0.04). IL1B change was predicted with the
changes in aortic root diameter (0.4, p 0.02), RVd (r 0.5, P 0.04), and PASP (r 0.5, P
0.03).
Conclusion: MS is associated with heightened inflammatory, platelet, thrombin, and
fibrinolytic activities that decrease after PMV. Altered hemodynamics might play a
possible role in some of these changes. Reduced inflammatory activity might have a
role in reduced platelet, thrombin, and fibrinolytic activities after PMV.
TCT-804
Effectiveness of Percutaneous Reduction of Significant Mitral Regurgitation of
Functional Etiology in High Surgical Risk Patients
Michael Argenziano1, William Gray1, Alfredo Trento2, Saibal Kar2, Elyse Foster3,
Laura Mauri4, Ted Feldman5, Donald Glower6
1Columbia University Medical Center, New York City, NY; 2Cedars-Sinai Medical
Center, Los Angeles, CA; 3University of California, San Francisco, CA; 4Brigham
and Women’s Hospital, Boston, MA; 5Evanston Northshore Healthcare, Evanston,
IL; 6Duke University Medical Center, Durham, NC
Background: Treatment of high surgical risk patients with significant functional mitral
regurgitation (FMR) is an important clinical challenge, as surgical correction of MR
may not always be a feasible option. The purpose of this analysis is to describe the
clinical benefit, including improvements in LV function and clinical symptoms,
observed following treatment with the MitraClip device in high surgical risk patients
with FMR.
Methods: EVEREST II High Surgical Risk Trial patients had significant MR (3+ or
4+) and were deemed high risk for surgery as predicted by a STS risk calculator
operative mortality of ≥ 12%, or surgeon assessment. Clinical outcomes included
NYHA Class, quality of life (QOL) measures, and echocardiographic measurements
by an independent core lab.
Results: 149 high surgical risk FMR patients underwent a MitraClip procedure with a
96% implant rate. A majority had prior cardiac surgery (63%), prior MI (57%) and
mean predicted surgical mortality by STS calculator of 11.3 ± 7.0%. Mortality at 30
days and 1 year was 5.4% and 23.9%, respectively. Of remaining patients with data at
baseline and 1 year, 101 had NYHA Class and 89 had matched echocardiograms, of
which 80% (71/89) achieved MR severity of 2+ or less. Significant improvements in
LV volumes, NYHA Class, and QOL (Table) were observed at 1 year.
Conclusion: The MitraClip procedure resulted in significant improvements in MR
severity, ventricular remodeling, and clinical outcomes and is an important therapeutic
option for select patients with significant functional MR who are at high risk for
surgical mortality.
TCT-805
Tissue-Doppler Assessment of The Changes in Longitudinal Left and Right
Ventricular Functions After Percutaneous Mitral Valvotomy
Hosam Hasan-Ali, Ayman Hassan
Cardiovascular Medicine, Assiut University Hospitals, Assiut, Egypt
Background: The effect of Percutaneous Mitral Valvotomy (PMV) on longitudinal
left and right ventricular systolic and diastolic functions assessed by pulsed-wave
tissue-Doppler imaging (PW-TDI) was not studied well before.
Methods: The study included 52 patients with mitral stenosis (age 26±8 years, 16
“32%” males, score 6.8±1.2, mitral valve area ≤1.5cm2, mitral regurgitation ≤ II/IV).
Longitudinal right and left ventricular functions were assessed before and 2 weeks
after PMV by PW-TDI. PW-TDI measurments of the septal, anterior, lateral and
inferior mitral annulus were taken as measurments of the longitudinal left ventricular
functions. Also, PW-TDI measurments at the lateral tricuspid annulus were taken as
measurments of the longitudinal right ventricular functions.
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